Frontiers in Oncology (Jan 2022)

A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer

  • Yu-Tien Chang,
  • Wen-Chiuan Tsai,
  • Wei-Zhi Lin,
  • Chia-Chao Wu,
  • Jyh-Cherng Yu,
  • Vincent S. Tseng,
  • Guo-Shiou Liao,
  • Je-Ming Hu,
  • Je-Ming Hu,
  • Je-Ming Hu,
  • Huan-Ming Hsu,
  • Huan-Ming Hsu,
  • Yu-Jia Chang,
  • Yu-Jia Chang,
  • Yu-Jia Chang,
  • Meng-Chiung Lin,
  • Meng-Chiung Lin,
  • Chi-Ming Chu,
  • Chi-Ming Chu,
  • Chi-Ming Chu,
  • Chi-Ming Chu,
  • Chien-Yi Yang

DOI
https://doi.org/10.3389/fonc.2021.759952
Journal volume & issue
Vol. 11

Abstract

Read online

BackgroundImmunoglobulin-related genes are associated with the favorable prognosis of triple-negative breast cancer (TNBC) patients. We aimed to analyze the function and prognostic value of immunoglobulin lambda constant 2 (IGLC2) in TNBC patients.MethodsWe knocked down the gene expression of IGLC2 (IGLC2-KD) in MDA-MB-231 cells to evaluate the proliferation, migration, and invasion of tumors via 3-(4,5-Dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, wound healing, and transwell cell migration assay respectively. Relapse-free survival (RFS) and distant metastasis-free survival (DMFS) analyses were conducted using the KM plotter online tool. The GSE76275 data set was used to analyze the association of IGLC2 and clinical characteristics. A pathway enrichment analysis was conducted using the next-generation sequencing data of wild-type and IGLC2-KD MDA-MB-231 cells.ResultsThe low gene expression of IGLC2 was related to unfavorable RFS, DMFS. The high expression of IGLC2 was exhibited in the basal-like immune-activated (BLIA) TNBC molecular subtype, which was immune-activated and showed excellent response to immune therapy. IGLC2 was positively correlated with programmed death-ligand 1 (PD-L1) as shown by Spearman correlation (r = 0.25, p < 0.0001). IGLC2 had a strong prognostic effect on lymph node-negative TNBC (RFS range: 0.31, q value= 8.2e-05; DMFS = 0.16, q value = 8.2e-05) but had no significance on lymph node-positive ones. The shRNA-mediated silencing of IGLC2 increased the proliferation, migration, and invasion of MDA-MB-231 cells. The results of pathway enrichment analysis showed that IGLC2 is related to the PI3K-Akt signaling pathway, MAPK signaling pathway, and extracellular matrix–receptor interaction. We confirmed that MDA-MB-231 tumor cells expressed IGLC2, subverting the traditional finding of generation by immune cells.ConclusionsIGLC2 linked with the proliferation, migration, and invasion of MDA-MB-231 cells. A high expression of IGLC2 was related to favorable prognosis for TNBC patients. IGLC2 may serve as a biomarker for the identification of TNBC patients who can benefit the most from immune checkpoint blockade treatment.

Keywords